EUCTR2005-005745-18-BE进行中（未招募）不适用
evamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial. - Levamisol Trial
Emma Children's Hospital-AMC0 个研究点目标入组 100 人开始时间: 2007年9月10日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Frequently relapsing idiopathic SSNS with or without steroid dependency
- •- Age between 2 and 18 years
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patient previously treated with Levamisole
- •- Patients unresponsive to Cyclosporine or MMF
- •- Nephrotic Syndrome due to specific kidney disease
- •- Patients presenting with leucopenia, convulsions or with hepatic diseases
研究者
相似试验
招募中
3 期
A clinical trial to study the effects of levamisole in children with steroid sensitive nephrotic syndromeCTRI/2009/091/000116Emma Childrens Hospital AMC100
已完成
不适用
evamisole treatment for children with steroid sensitive nephrotic syndromeephrotic syndromeUrological and Genital DiseasesNephrotic syndromeISRCTN23853712Academic Medical Centre (AMC) (Netherlands)100
招募中
不适用
evamisole treatment for children with steroid sensitive nephrotic syndrome.steroid sensitive idiopathic nephrotic syndrome(steroid gevoelig idiopathisch nefrotisch syndroom), relapse (recidief), levamisole, steroid side effects (steroid bijwerkingen),NL-OMON26305Academic Medical Center of AmsterdamMeibergdreef 9, 1105 AZ Amsterdam Z-OThe Netherlands100
已完成
不适用
evamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitaemiaSevere falciparum malaria with high parasitaemiaInfections and InfestationsMalariaISRCTN27232551niversity of Oxford (United Kingdom)60
进行中（未招募）
不适用
Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of inhaled steroidsAsthmaEUCTR2007-000097-23-NLGlaxoSmithKline